QUINTILES IMS HOLDINGS, INC. (NYSE:Q) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 27, 2016, the Leadership Development and Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Quintiles IMS Holdings, Inc. (the “Company”) approved the termination of the adoption of the Quintiles Transnational Corp. 401(k) Restoration Plan (the “Restoration Plan”), effective December 30, 2016 and approved adoption of the Quintiles IMS Savings Equalization Plan (the “Savings Equalization Plan”) effective December 31, 2016. The Board terminated the Restoration Plan and adopted the Savings Equalization Plan in order to provide similar benefits as the Restoration Plan, but with less related tax and administrative complexities.

The Company’s Savings Equalization Plan is an unfunded, non-qualified defined contribution plan that is offered to certain eligible U.S.-based employees, including the Company’s named executive officers who participate in the Quintiles Transnational Corp. 401(k) plan. The Savings Equalization Plan provides a benefit equal to the amount by which the Company’s contribution is limited under the tax-qualified 401(k) savings plan due to applicable Internal Revenue Code limits. Benefits under the Savings Equalization Plan are provided in the form of cash payment made within 75 days after the end of the calendar year to which it relates.

About QUINTILES IMS HOLDINGS, INC. (NYSE:Q)

Quintiles IMS Holdings Inc, formerly Quintiles Transnational Holdings Inc., is a provider of biopharmaceutical development services and commercial outsourcing services. It is engaged in the development and commercialization of pharmaceutical therapies. Its segments include Product Development and Integrated Healthcare Services. Its Product Development segment is a contract research organization and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. The Integrated Healthcare Services segment includes commercial pharmaceutical sales and service organizations, and provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services for the healthcare sector, such as phase research, market access and consulting, health information analytics and technology consulting, and other healthcare solutions.

QUINTILES IMS HOLDINGS, INC. (NYSE:Q) Recent Trading Information

QUINTILES IMS HOLDINGS, INC. (NYSE:Q) closed its last trading session up +0.17 at 76.05 with 848,611 shares trading hands.